Pittsboro, NC – November 11, 2020 – Christopher Crean, Founder and Principal Consultant at Xyzagen, was featured in a cover article of Pharmatech Outlook’s Bioanalytical Services Edition, highlighting his perspective on the evolving drug discovery and CRO landscape.
Pharma Tech Outlook’s Bioanalytical Services Edition is a specialized issue of the magazine that highlights top-performing contract research organizations (CROs) and service providers in the bioanalysis sector.
In the feature, Christopher shares his perspective on how early-stage biotech companies are reshaping drug discovery, and why integrated pharmacokinetics, bioanalysis, and scientific consulting are critical to advancing programs efficiently in today’s CRO landscape.
Article Excerpt:
Powering The Evolving Drug Discovery Landscape
The pharmaceutical drug discovery industry is evolving. Innovations in the sector are more and more powered by seed, NIH, and VC-funded companies that are either spun out of academic institutions or are being incubated by venture capital firms based on licensed technology or public-private partnerships. In parallel, a wave of mergers and acquisitions is happening on the scientific operations and process side of pharmaceutical research due to the stability and growth of pharmaceutical outsourcing.
CROs have been aggregating and thus expanding their service areas to be more of a single source provider within either testing, regulatory, or manufacturing. This narrowing field of nonclinical, clinical, bioanalytical, and manufacturing CROs that provide full support to large pharma are also looking to support the smaller innovators with their breadth of capabilities.
These organizations are not just located within the US, and thus this reordering of “who does what” has also led to the expanded importance of individual consultants with scientific discipline expertise within the industry and the growing role of consultancy organizations that support early innovators navigating the changing regulatory and CRO landscape while also quickly advancing their client’s research program…
The feature in Pharmatech Outlook highlights Xyzagen’s role in supporting early-stage innovators through integrated pharmacokinetics, bioanalysis, and strategic scientific consulting.
You can view the full cover feature here: Powering The Evolving Drug Discovery Landscape (PDF Download)
About Xyzagen, Inc.
Xyzagen augments a client’s pharmacology and pharmacokinetics drug development team. As a leading pharmacokinetics consultancy and contract research organization with wet lab and rodent vivarium facilities, Xyzagen is able to push model informed drug development into its First-in-Rat® and First-in-Mouse® discovery platforms as well as support late stage clinical noncompartmental PK, PopPK and Quantitative Medicine.Our knowledge in pharmacology and pharmacokinetics allows the client to expand their core scientific team during the critical period of candidate selection up to the PreIND meeting and through clinical development and the preNDA meeting. Xyzagen’s a boutique organization which allows small clients to work directly and strategically with experts during their drug development programs.
Media Contact:
Christopher Crean
Founder & CEO
Xyzagen, Inc.
Phone: 919-726-2072
Email: [email protected]
